Cytokine inhibition as a strategy for treating systemic lupus erythematosus
- 30 September 2013
- journal article
- review article
- Published by Elsevier BV in Clinical Immunology
- Vol. 148 (3), 335-343
- https://doi.org/10.1016/j.clim.2012.11.001
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- IFN-α and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cellsProceedings of the National Academy of Sciences of the United States of America, 2011
- Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in miceKidney International, 2011
- Anti-TNF-α Therapies in Systemic Lupus ErythematosusJournal of Biomedicine and Biotechnology, 2010
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage‐escalation studyArthritis & Rheumatism, 2010
- Trans-presentation: A novel mechanism regulating IL-15 delivery and responsesImmunology Letters, 2010
- Identification ofIRAK1as a risk gene with critical role in the pathogenesis of systemic lupus erythematosusProceedings of the National Academy of Sciences of the United States of America, 2009
- Immunological and Inflammatory Functions of the Interleukin-1 FamilyAnnual Review of Immunology, 2009
- Phenotypic and functional features of human Th17 cellsThe Journal of Experimental Medicine, 2007
- Cytokines in the pathogenesis of rheumatoid arthritisNature Reviews Immunology, 2007
- A crucial role for interleukin (IL)-1 in the induction of IL-17–producing T cells that mediate autoimmune encephalomyelitisThe Journal of Experimental Medicine, 2006